Abstract Library

#4573 Digestive neuroendocrine tumours: Patterns, pathways, and progress in personalised management

Introduction: Digestive neuroendocrine tumours (NETs), though rare, are increasingly diagnosed with their incidence rising. Histopathological examination is crucial for diagnosis and grading, based on cell differentiation and proliferation index. Often diagnosed late due to non-specific symptoms, these tumours may present with hormone hypersecretion. Updated classifications now allow better risk stratification and tailored treatments. Advances in imaging, particularly PETscans with somatostatin analogues have improved NET diagnosis and monitoring.

Conference:

Presenting Author: Bensetti Houari A

Authors: Bensetti Houari A, Remouche H, Belkharoubi K,

Keywords: Digestive neuroendocrine tumour, octreoscan, multidisciplinary approach,

#4460 Digestive neuroendocrine tumours G1 and G2: Experience of the medical oncology department at the Oran University Hospital Establishment 1st November 1954

Introduction: The histological classification of neuroendocrine tumours (NETs) remains complex, and their grading is a major prognostic factor, essential for guiding appropriate management. Moreover, NETs raise unresolved histogenetic questions. The treatment of grade 1 (G1) NETs primarily relies on somatostatin analogues, while grade 2 (G2) NETs, being more heterogeneous, may require management that includes chemotherapy or targeted therapy.

Conference:

Presenting Author:

Authors: Kehili H, Bengueddache A, Boumansour N, Larbi Bounsbia L, Bechikh A,

Keywords: Digestive Neuroendocrine Tumour, Grade 1, Grade 2, Somatostatin Analogue,

#4352 What can a reference centre offer to patients? Evolution of first visits for neuroendocrine and endocrine tumours and its relation to clinical trials availability.

Introduction: Endocrine and neuroendocrine neoplasia (NEN), which include gastroenteropancreatic neuroendocrine tumours, thyroid cancer and adrenal carcinoma, have a low incidence, making their diagnosis and treatment difficult. Due to this complexity, patients should be managed at specialised centres; however, the lack of official referral networks complicates the concentration of cases.

Conference:

Presenting Author: Martinez-Badal S

Authors: Martínez-Badal S, Hernando Cubero J, García Alvarez A, Elguero B, Alcantara A,

Keywords: Neuroendocrine, Clinical Trial, Reference Centre, Patient referral,

#4245 Carcinoid heart in neuroendcrine tumor – Experience of medical departement oncology Oran, Algeria

Introduction: The carcinoid heart is present in approximately 20% of cases at the diagnosis of carcinoid dyndrome in neuroendocrine tumors, and will occur in approximately 50% of patients during follow-up. The consequence is the appearance of stenosing and/or leaking valvular diseases, responsible, eventually, right or left ventricular dysfunction and severe heart failure. Only surgical valve replacement treatment seems to be able to improve the prognosis, but at the cost of significant perioperative morbidity and mortality.

Conference:

Presenting Author: Kaid M

Authors: Kaid M, Bengueddach A, Bennaoum A, Kehili H, Bereksi-Reguig F,

Keywords: carcinoid heart disease, somatostatin,

#4225 Digestive neuroendocrine tumors – Retrospective study and experience of the general surgery department of EHU Oran

Introduction: Neuroendocrine tumors are rare tumors and represent 1% of all digestive tumors, their incidence has seen a constant increase in recent decades, possibly linked to better diagnostic methods and better knowledge of these tumors. Surgery remains the only curative treatment for localized endocrine tumors. The rarity and heterogeneity of these tumors makes their management difficult and explains the low number of randomized studies and the associated low level of evidence.

Conference:

Presenting Author:

Authors: Bennaoum S, Kaid M,

Keywords: surgery, neuroendcrine digestive tumor,